ASSET
ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours
| Coordinatore |
Organization address
address: BELFIELD contact info |
| Nazionalità Coordinatore | Non specificata |
| Totale costo | 16˙155˙200 € |
| EC contributo | 11˙999 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-11-01 - 2016-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Organization address
address: BELFIELD contact info |
IE (DUBLIN) | coordinator | 1˙924˙743.53 |
| 2 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | participant | 1˙481˙309.75 |
| 3 | KOBENHAVNS UNIVERSITET | DK | participant | 1˙200˙351.60 |
| 4 |
INSTITUT CURIE
Organization address
address: 26, rue d'Ulm contact info |
FR (PARIS) | participant | 860˙800.00 |
| 5 |
ST. ANNA KINDERKREBSFORSCHUNG
Organization address
address: ZIMMERMANNPLATZ 10 contact info |
AT (WIEN) | participant | 822˙392.00 |
| 6 |
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Organization address
address: Dr. Ignaz Seipel-Platz 2 contact info |
AT (WIEN) | participant | 803˙818.25 |
| 7 |
UNIVERSITEIT GENT
Organization address
address: SINT PIETERSNIEUWSTRAAT 25 contact info |
BE (GENT) | participant | 790˙400.00 |
| 8 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | participant | 730˙800.00 |
| 9 |
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: TEKNIIKANTIE 4 A contact info |
FI (ESPOO) | participant | 652˙908.00 |
| 10 |
WEIZMANN INSTITUTE OF SCIENCE
Organization address
address: HERZL STREET 234 contact info |
IL (REHOVOT) | participant | 486˙912.00 |
| 11 |
UNIVERSITAETSKLINIKUM ESSEN
Organization address
address: HUFELANDSTRASSE 55 contact info |
DE (ESSEN) | participant | 470˙603.56 |
| 12 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | participant | 419˙774.00 |
| 13 |
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
Organization address
address: REGINA PACIS WEG 3 contact info |
DE (BONN) | participant | 320˙529.00 |
| 14 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 306˙816.44 |
| 15 |
BAYER SCHWEIZ AG
Organization address
address: GRUBENSTRASSE 6 contact info |
CH (ZURICH) | participant | 276˙532.00 |
| 16 |
THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
UK (COVENTRY) | participant | 261˙676.67 |
| 17 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 188˙789.40 |
| 18 |
BAYER TECHNOLOGY SERVICES GMBH
Organization address
address: Kaiser-Wilhelm-Allee contact info |
DE (LEVERKUSEN) | participant | 0.00 |
| 19 |
Teknologian tutkimuskeskus VTT Oy
Organization address
address: Vuorimiehentie 3 contact info |
FI (Espoo) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact by focussing on unravelling the signalling networks and their alterations in ETs. The basic hypothesis is that ETs share common pathogenetic principles that can be captured and made accessible to rational analysis by combining high-throughput and high content analysis of the genome, transcriptome and proteome with mathematical modelling. ASSET builds on a previous FP6 consortium, the European Embryonal Tumour Pipeline (EEPT), which generated high-throughput genomic and transcriptomic data on ETs. ASSET is the next logical step to add crucial functional information that will allow us to generate (i) defined in vitro and in vivo tumour systems; (ii) combined analysis of genomic mutations, transcriptome, miRNA expression and dynamic proteome changes; (iii) systematic perturbations; (iv) mathematical modelling to elucidate pathogenetic networks and their emergent behaviour; (v) the virtuous cycle of model validation in relevant biological model systems and clinical samples towards a major goal. This goal is to identify mechanistically understood network vulnerabilities that can be exploited for new approaches to the diagnosis and treatment of major paediatric tumours. Elucidating such core mechanisms will (i) improve understanding of and therapeutic options for these devastating childhood malignancies and (ii) enable a rational approach to deal with the complexity of the pathogenesis of adulthood cancers.'
Introduzione (Teaser)
Embryonal tumours (ETs) such as neuroblastoma (NB), medulloblastoma (MB) and Ewing sarcoma family tumours (ESFTs) occur in babies and children and have limited treatment options. ASSET, an EU-funded project, will find common ET-specific aberrations in core signalling networks by combining genomics, proteomics and mathematical modelling for effective diagnosis and therapy.